{"id":406,"company":{"country":"FR","currency":"EUR","exchange":"NYSE EURONEXT - EURONEXT PARIS","ipo":"2002-07-01","marketCap":109569.6484375,"name":"Sanofi SA","phone":"33153774000.0","outstanding":1253.8800048828125,"symbol":"SNY","website":"https://www.sanofi.com/","industry":"Pharmaceuticals"},"price":46.680023,"year":2023,"month":11,"day":3,"weekday":"Friday","title":"Evaluating the Impact of Changes in Trade Agreements on Sanofi SA's Global Operations and Stock Price","date":"2023-11-03","url":"/posts/2023/11/03/SNY","content":[{"section":"Introduction","text":"Trade agreements and international relations play a significant role in shaping the operations and stock price of multinational corporations such as Sanofi SA. Changes in trade policies and diplomatic relationships can have both positive and negative impacts on a company's business prospects and financial performance."},{"section":"Impact on Global Operations","text":"Changes in trade agreements can affect Sanofi SA's global operations in several ways. Firstly, alterations in tariffs, import/export regulations, and intellectual property rights can impact the company's ability to efficiently conduct its operations across international markets. Higher trade barriers may increase the cost of importing raw materials or exporting finished products, thereby affecting the company's profitability. Additionally, changes in regulatory frameworks can affect the approval and distribution of Sanofi's pharmaceutical products in different countries, impacting its market access and sales."},{"section":"Impact on Stock Price","text":"Changes in trade agreements or international relations can also influence Sanofi SA's stock price. Uncertainty surrounding trade policies can lead to market volatility, with investors reacting to potential disruptions in the company's supply chains or changes in revenue streams. Negative developments in trade relations may lead to a decrease in investor confidence and a decrease in Sanofi's stock price. On the other hand, positive developments, such as the removal of trade barriers or improved international relations, may boost investor sentiment, leading to an increase in stock price."},{"section":"Global Political Dynamics and Business","text":"Global political dynamics have a profound impact on businesses, particularly multinational corporations operating in multiple countries. Changes in diplomatic relations between countries can result in trade disputes, tariffs, or other protectionist measures. These developments can disrupt supply chains, increase costs, and hinder market access. Additionally, political instability or conflicts in certain regions can pose risks to a company's operations, including potential disruptions in production, distribution, or workforce availability. Multinational corporations like Sanofi SA must closely monitor global political dynamics to anticipate and mitigate potential risks to their operations and stock prices."},{"section":"Conclusion","text":"In conclusion, changes in trade agreements and international relations can significantly impact Sanofi SA's global operations and stock price. Trade policy shifts can affect the company's ability to efficiently conduct its business across international markets, while changes in diplomatic relationships can influence investor sentiment and market volatility. Furthermore, global political dynamics, including trade disputes and political instability, can pose risks and challenges for multinational corporations. Sanofi SA and other businesses must navigate these complexities, adapt to changing conditions, and develop strategies to mitigate potential risks and maximize opportunities for growth."}],"tags":["CrossUnder100","Short","Pharmaceuticals"],"news":[{"category":"company","date":1698942660,"headline":"Regeneron (REGN) Q3 Earnings \u0026 Sales Top, Eylea Sales Decline","id":123572475,"image":"https://media.zenfs.com/en/zacks.com/5191fe24e96559c2d90d0319223c2771","symbol":"SNY","publisher":"Yahoo","summary":"Regeneron (REGN) beats earnings and sales estimates in third-quarter 2023, fueled by Dupixent. However, sales of the lead drug, Eylea, fall yet again.","url":"https://finance.yahoo.com/news/regeneron-regn-q3-earnings-sales-163100485.html"},{"category":"company","date":1698941700,"headline":"Sanofi honors 10 advocacy organizations promoting health equity solutions in underserved U.S. communities","id":123572476,"image":"https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png","symbol":"SNY","publisher":"Yahoo","summary":"Sanofi has announced the winners of its 2023 Health Equity Accelerator Awards, honoring 10 nonprofit organizations that exemplify the company's ambition to provide equitable access to healthcare using innovative solutions for hard-to-solve health disparities.","url":"https://finance.yahoo.com/news/sanofi-honors-10-advocacy-organizations-161500318.html"},{"category":"company","date":1698929019,"headline":"Kymera Therapeutics Inc (KYMR) Announces Q3 2023 Financial Results","id":123572477,"image":"https://media.zenfs.com/en/us.finance.gurufocus/6418b62081c0763a132923f3dfe000a3","symbol":"SNY","publisher":"Yahoo","summary":"Company reports a net loss of $52.9 million and a cash balance of $435 million","url":"https://finance.yahoo.com/news/kymera-therapeutics-inc-kymr-announces-124339971.html"},{"category":"company","date":1698915600,"headline":"Pfizer: Value Investment Opportunity After Recent Price Decline","id":123569939,"image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/121279005/image_121279005.jpg?io=getty-c-w1536","symbol":"SNY","publisher":"SeekingAlpha","summary":"Pfizer still generates significant gross profit and has a strong revenue growth rate. Read why I feel PFE stock presents a value investment opportunity now.","url":"https://seekingalpha.com/article/4646398-pfizer-value-investment-opportunity-after-recent-price-decline"},{"category":"company","date":1698836400,"headline":"Sanofi launches \"The 1 Pledge\" movement to drive early screening for type 1 diabetes in the U.S.","id":123558777,"image":"https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png","symbol":"SNY","publisher":"Yahoo","summary":"Sanofi, a leader in diabetes care, today launched \"The 1 Pledge\" movement, a nationwide education campaign urging families to get screened for type 1 diabetes so that those who will eventually be affected by the disease can begin to prepare as soon as possible.","url":"https://finance.yahoo.com/news/sanofi-launches-1-pledge-movement-110000856.html"},{"category":"company","date":1698830820,"headline":"Biotech Alert: Searches spiking for these stocks today","id":123545642,"image":"","symbol":"SNY","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3189131609"},{"category":"company","date":1698822480,"headline":"Ligand acquires Tolerance Therapeutics for $20M in cash","id":123546107,"image":"","symbol":"SNY","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3188935560"},{"category":"company","date":1698765910,"headline":"Analyzing The Acquisition Potential Of ImmunoGen","id":123527107,"image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1371706582/image_1371706582.jpg?io=getty-c-w1536","symbol":"SNY","publisher":"SeekingAlpha","summary":"ImmunoGen has an approved drug, a modest pipeline with a catalyst upcoming, and a market cap of around $3.6 billion. Find out why IMGN stock is a Buy.","url":"https://seekingalpha.com/article/4645518-analyzing-the-acquisition-potential-of-immunogen"},{"category":"company","date":1698756420,"headline":"Sanofi price target lowered to EUR 105 from EUR 115 at Berenberg","id":123538985,"image":"","symbol":"SNY","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3187385860"},{"category":"company","date":1698755098,"headline":"Amicus Therapeutics: The Right Play Now","id":123522478,"image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1422967687/image_1422967687.jpg?io=getty-c-w1536","symbol":"SNY","publisher":"SeekingAlpha","summary":"Amicus Therapeutics, Inc. is a biotech company developing therapies for rare diseases. Click here to read my analysis on FOLD stock now.","url":"https://seekingalpha.com/article/4645407-amicus-therapeutics-the-right-play-now"},{"category":"company","date":1698714960,"headline":"Analyst Maintains Buy Rating for Sanofi Despite Challenges, Foresees Future Growth and Outperform Potential","id":123537448,"image":"","symbol":"SNY","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3186562514"},{"category":"company","date":1698698154,"headline":"13 Most Undervalued Pharma Stocks To Buy According To Analysts","id":123505333,"image":"","symbol":"SNY","publisher":"Yahoo","summary":"In this piece, we will take a look at the 13 most undervalued pharmaceutical stocks to buy according to analysts. If you want to skip our overview of the pharma industry, then check out 5 Most Undervalued Pharma Stocks To Buy. The pharmaceutical industry is one of the biggest in the world and one that […]","url":"https://finance.yahoo.com/news/13-most-undervalued-pharma-stocks-203554710.html"},{"category":"company","date":1698678266,"headline":"Sanofi stock recovers slightly after last week's plunge","id":123498756,"image":"https://s.yimg.com/ny/api/res/1.2/NkE.1oJRCAOZb4kbpHvEAw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzY-/https://s.yimg.com/os/creatr-uploaded-images/2023-10/66a3ae90-7731-11ee-a6fd-8f7cdded5f1a","symbol":"SNY","publisher":"Yahoo","summary":"Sanofi (SNY) shares are trending higher after plummeting last Friday on the pharmaceutical company's third-quarter earnings miss, losing over $21 billion in market value. Sanofi announced plans to spin off its consumer health division, with CEO Paul Hudson stating the spinoff aims to enhance the company's \"cost structure\" and aid them in \"becoming a pure play biopharma company.\" Yahoo Finance's Anjalee Khemlani explores Sanofi's decision and the growing trend of pharmaceutical companies spinning off their consumer segments in recent years. For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live.","url":"https://finance.yahoo.com/video/sanofi-announces-spinoff-plan-stock-150426466.html"},{"category":"company","date":1698669875,"headline":"AbbVie shares rise after Barclays upgrades rating of U.S. drugmaker","id":123507886,"image":"https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png","symbol":"SNY","publisher":"Yahoo","summary":"Investing.com -- Shares in AbbVie (NYSE:ABBV) rose on Monday after analysts at Barclays raised their rating and price target for the drugmaker, calling a temporary drop in the stock at the end of last week an \"over-reaction\" to a strategy shift from rival Sanofi (NASDAQ:SNY) that hit the wider biopharmaceutical sector.","url":"https://finance.yahoo.com/news/abbvie-shares-rise-barclays-upgrades-124435541.html"},{"category":"company","date":1698668700,"headline":"Sanofi invests in MeiraGTx and its gene-regulating technology","id":123572478,"image":"https://www.biopharmadive.com/imgproxy/r0q0HUKeYYMKsA3qDpXJ7o_l6jVwPojotnEOC2uud38/crop:6880:3887/g:nowe:0:1235/rs:fill:770:435:0/bG9jYWw6Ly8vZGl2ZWltYWdlLzQ5NjkwNzgzNzEyXzJhNzVmZDkzYzJfby5qcGc.jpg","symbol":"SNY","publisher":"Yahoo","summary":"In addition to Sanofi’s investment, the biotech signaled it’s weighing deals with “multiple” other companies that have expressed interest in its work.","url":"https://www.biopharmadive.com/news/sanofi-meira-gtx-invest-gene-riboswitch/698145/"},{"category":"company","date":1698663540,"headline":"What You Missed On Wall Street This Morning","id":123498643,"image":"","symbol":"SNY","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3185230782"},{"category":"company","date":1698662700,"headline":"MeiraGTx Shares Jump 34% After Sanofi Investment","id":123525421,"image":"https://mw3.wsj.net/mw5/content/logos/mw_logo_social.png","symbol":"SNY","publisher":"MarketWatch","summary":"By Will Feuer Shares of MeiraGTx Holdings rose after the gene-therapy company said it has received a $30 million investment from French pharmaceutical...","url":"https://www.marketwatch.com/story/meiragtx-shares-jump-34-after-sanofi-investment-77f8f760"},{"category":"company","date":1698658200,"headline":"Sanofi and Insight Enterprises CEOs: With the right blueprint in place, AI will empower workers and help big companies become more nimble","id":123495196,"image":"https://s.yimg.com/ny/api/res/1.2/QENUM7UhPlMIszu34XzjDg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/fortune_175/af59feb04342e214a15ba3a92ac60618","symbol":"SNY","publisher":"Yahoo","summary":"Sanofi CEO Paul Hudson and Insight CEO Joyce Mullen say that for leaders who integrate AI mindfully, 'the resulting force will be unrivaled.'","url":"https://finance.yahoo.com/news/sanofi-insight-enterprises-ceos-blueprint-093000513.html"},{"category":"company","date":1698654540,"headline":"MeiraGTx (NASDAQ:MGTX) Surges After Sanofi’s $30 Million Investment","id":123503351,"image":"","symbol":"SNY","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3185030339"},{"category":"company","date":1698654480,"headline":"MeiraGTx shares jump as Sanofi invests in gene therapy ","id":123525422,"image":"https://mw3.wsj.net/mw5/content/logos/mw_logo_social.png","symbol":"SNY","publisher":"MarketWatch","summary":"Sanofi may use company's gene regulation technology in immunology, metabolic disease and other conditions","url":"https://www.marketwatch.com/story/meiragtx-shares-jump-as-sanofi-invests-in-gene-therapy-30ffc2cf"},{"category":"company","date":1698651840,"headline":"MeiraGTx Gets $30 Million Investment From Sanofi","id":123525423,"image":"https://mw3.wsj.net/mw5/content/logos/mw_logo_social.png","symbol":"SNY","publisher":"MarketWatch","summary":"By Will Feuer MeiraGTx Holdings said it has received a $30 million investment from French pharmaceutical company Sanofi, and said the company has been...","url":"https://www.marketwatch.com/story/meiragtx-gets-30-million-investment-from-sanofi-3acac604"},{"category":"company","date":1698651720,"headline":"GLOBAL BROKER RATINGS: Stifel cuts Mercedes and Sanofi to 'hold'","id":123497363,"image":"","symbol":"SNY","publisher":"Alliance News","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=uobjs6o44f"},{"category":"company","date":1698650940,"headline":"MeiraGTx shares jump as Sanofi invests in gene therapy","id":123503359,"image":"","symbol":"SNY","publisher":"MarketWatch","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3184957008"},{"category":"company","date":1698648300,"headline":"Deutsche Bank Sticks to Its Sell Rating for Sanofi (SNYNF)","id":123503013,"image":"","symbol":"SNY","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3184911683"},{"category":"company","date":1698647640,"headline":"MeiraGTx announces $30M strategic investment from Sanofi","id":123503361,"image":"","symbol":"SNY","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3184900431"},{"category":"company","date":1698644100,"headline":"Sanofi price target lowered to EUR 122 at BofA, says selloff 'hugely overdone'","id":123506872,"image":"","symbol":"SNY","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3184845757"},{"category":"company","date":1698640260,"headline":"Sanofi price target lowered to EUR 95 from EUR 115 at Barclays","id":123506873,"image":"","symbol":"SNY","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3185747315"},{"category":"company","date":1698640080,"headline":"Sanofi downgraded to Hold from Buy at Stifel","id":123506874,"image":"","symbol":"SNY","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3184791160"},{"category":"company","date":1698635220,"headline":"Sanofi’s Increased R\u0026D Spending and Potential Value: An Argument for a Buy Rating","id":123503014,"image":"","symbol":"SNY","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3184733987"},{"category":"company","date":1698633960,"headline":"Apple, AMD, Palantir Earnings On Deck This Week As Market Seeks Positive Catalysts In Fed Decision Week","id":123497176,"image":"","symbol":"SNY","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3184719796"},{"category":"company","date":1698632100,"headline":"Sanofi price target lowered to EUR 80 from EUR 90 at Deutsche Bank","id":123506877,"image":"","symbol":"SNY","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3185518999"},{"category":"company","date":1698606136,"headline":"Sanofi (NASDAQ:SNY) Q3 2023 Earnings Call Transcript","id":123492528,"image":"https://media.zenfs.com/en/insidermonkey.com/c182d8444c4e81349a0311790db473ce","symbol":"SNY","publisher":"Yahoo","summary":"Sanofi (NASDAQ:SNY) Q3 2023 Earnings Call Transcript October 27, 2023 Eva Schaefer-Jansen: [starts abruptly] You have joined the meeting as an attendee and will be muted throughout the meeting. This meeting is being recorded. 2023 results followed by a Q\u0026A session. As usual, you can find the slides to this call on the investors page […]","url":"https://finance.yahoo.com/news/sanofi-nasdaq-sny-q3-2023-190216921.html"},{"category":"company","date":1698577500,"headline":"Pharma, PBMs spar over rising drug costs amid public scrutiny","id":123483527,"image":"","symbol":"SNY","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3184120530"},{"category":"company","date":1698564047,"headline":"Sanofi Spins Off, Investors Spin Out (Rating Downgrade)","id":123482139,"image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1137334745/image_1137334745.jpg?io=getty-c-w1536","symbol":"SNY","publisher":"SeekingAlpha","summary":"Sanofi's Q3 2023 shows mixed results with net sales down 4.1% YoY, and operating income falling 11.2%. Learn why I downgrade SNY stock to a hold.","url":"https://seekingalpha.com/article/4644850-sanofi-spins-off-investors-spin-out-rating-downgrade"},{"category":"company","date":1698437031,"headline":"Sanofi Stock Crashes 19% As Drugmaker's Third Quarter Comes In Light Ahead Of Spinoff","id":123461305,"image":"","symbol":"SNY","publisher":"Yahoo","summary":"Sanofi stock crashed Friday after the company reported light third-quarter earnings and sales, and unveiled a looming spinoff.","url":"https://finance.yahoo.com/m/d27f839c-2816-37c0-8c71-58cc30be0a24/sanofi-stock-crashes-19%25-as.html"},{"category":"company","date":1698435840,"headline":"Ford forecast, Sanofi, Juniper Networks: Top Stocks","id":123461306,"image":"https://s.yimg.com/ny/api/res/1.2/J3ygd6PwcSVaWXkRKya5rg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzY-/https://s.yimg.com/os/creatr-uploaded-images/2023-10/27743b90-7501-11ee-aadc-ff61f14973a1","symbol":"SNY","publisher":"Yahoo","summary":"Shares of the Big Three automakers — Ford (F), General Motors (GM), Stellantis (STLA) — edge lower ahead of Friday's close after Ford reached a tentative labor agreement with striking United Auto Workers (UAW) membership on October 26. While GM and Stellantis are reportedly in talks with the UAW, Ford pulls back on its 2023 forecast fearing higher-than-expected losses in its EV business. Sanofi (SNY) stock dives nearly 20% ahead of Friday's closing bell after disappointing on earnings this quarter and warning of slowing earnings growth in 2024. Cloud developer Juniper Networks (JNPR) stock jumps after reporting strong third-quarter earnings and growth in its enterprise business. Yahoo Finance's Julie Hyman and Josh Lipton take a look at several of the day's top trending stocks. For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live.","url":"https://finance.yahoo.com/video/ford-forecast-sanofi-juniper-networks-194400777.html"},{"category":"company","date":1698435022,"headline":"Sanofi (SNY) Q3 2023 Earnings Call Transcript","id":123461307,"image":"","symbol":"SNY","publisher":"Yahoo","summary":"Thank you for joining us to review Sanofi's third quarter 2023 results, followed by a Q\u0026A session.  The global business unit heads, Brian Foard, Thomas Triomphe, and Olivier Charmeil will join for Q\u0026A to which you have two options to participate.","url":"https://finance.yahoo.com/m/1c5557ed-51c2-3ab2-973f-a9b51cc64b06/sanofi-%28sny%29-q3-2023-earnings.html"},{"category":"company","date":1698431040,"headline":"Why Drug Companies Don’t Want to Sell Allergy Medicines and Bandages Anymore","id":123461308,"image":"https://s.yimg.com/ny/api/res/1.2/V74fKREWNRmrVTLowA4a9A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02MDA-/https://media.zenfs.com/en/wsj.com/5e0d95c2595433f82cdcc3be79c5e8cf","symbol":"SNY","publisher":"Yahoo","summary":"Big Pharma is almost finished with the cough and cold medicine business.  French drug giant  Sanofi  said Friday it plans to spin off its consumer-health business, which includes well-known brands like allergy medicine Allegra and the pain treatments IcyHot and Aspercreme.  The drugmaker is the latest—after rivals  Johnson \u0026 Johnson Pfizer  and  GSK  —to hive off a division selling over-the-counter medicines and other retail products to focus on more commercially lucrative but scientifically riskier prescription drugs.","url":"https://finance.yahoo.com/m/be3bec03-165d-3bdd-b229-cb38faefc40e/why-drug-companies-don%E2%80%99t-want.html"},{"category":"company","date":1698429540,"headline":"Sanofi’s Lousy Outlook Is Bruising Its Stock—and Shocking Pharma Investors","id":123461309,"image":"https://media.zenfs.com/en/wsj.com/7b2c285183be07ca3c4e8242b25a59a8","symbol":"SNY","publisher":"Yahoo","summary":"Sanofi called its update to investors on Friday its [“Play to Win Strategy.”](https://www.sanofi.com/assets/dotcom/pressreleases/2023/2023-10-27-05-30-00-2768148-en.pdf) The announcement turned out to be one of the biggest losers for Big Pharma in years.  The U.S.-traded shares of Sanofi, known for Lantus insulin among other drugs, tumbled 19%, shocking Wall Street observers not accustomed to seeing the French pharma company’s stock—let alone any pharmaceutical stock—move so much.  “If this move in Sanofi holds, it would be the largest negative single-day stock move across Global Pharma in more than ten years,” wrote Jared Holz, a healthcare-equity strategist at Mizuho.","url":"https://finance.yahoo.com/m/c7b59956-b141-35f1-8a7f-7580fe3f36b6/sanofi%E2%80%99s-lousy-outlook-is.html"},{"category":"company","date":1698421020,"headline":"Sanofi Will Spin Out Its Consumer Health Division and 2024 Guidance Disappoints. The Stock Is Diving.","id":123461310,"image":"https://s.yimg.com/ny/api/res/1.2/4TmXueieml5ZBsM1u__sOg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02MDA-/https://media.zenfs.com/en/Barrons.com/1344e405ebe8e4ed4bb31a757f239694","symbol":"SNY","publisher":"Yahoo","summary":"The stand-alone division will be the latest addition to a growing list of such public companies recently spun out of larger drugmakers.","url":"https://finance.yahoo.com/m/e2daebf8-6369-329c-b258-5df09d601ac7/sanofi-will-spin-out-its.html"},{"category":"company","date":1698420789,"headline":"Sanofi shares fall 19% after cut to profit outlook","id":123461311,"image":"","symbol":"SNY","publisher":"Yahoo","summary":"Shares in Sanofi fell 19 per cent on Friday after the French pharmaceutical group announced a lower profit outlook and a spinout of its consumer care unit as it seeks to focus on drug research.  Sanofi reaffirmed its earnings per share guidance this year but projected a decline in the low-single digits in 2024 partly due to increased R\u0026D investment.  “We understand there is short-term disappointment and that the market wants certainty, but that would mean not maximising the company’s value,” chief executive Paul Hudson told analysts on Friday.","url":"https://finance.yahoo.com/m/bc17cb85-7bce-31b4-abd5-447162ab0c9d/sanofi-shares-fall-19%25-after.html"},{"category":"company","date":1698419700,"headline":"Sanofi CEO Shocks Investors With Investment Plan, Few Details","id":123463973,"image":"https://s.yimg.com/ny/api/res/1.2/3ZUOD8rCdubq.ks9Miv1Vg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/bloomberg_markets_842/bedbc84d5054a93ecd401c4e64537cb2","symbol":"SNY","publisher":"Yahoo","summary":"(Bloomberg) -- When the day began, Paul Hudson, Sanofi’s perennially upbeat chief executive officer, was sitting pretty with a double-digit share gain this year, a world-beating drug in Dupixent and few of the patent cliff worries weighing on his big pharma rivals. Most Read from BloombergIsrael Latest: Iranian Minister Warns US Over Support of IsraelHouse Speaker Mike Johnson’s First Big Bill Cuts Biden’s Climate Change FundingEverything Apple Plans to Launch at Oct. 30 ‘Scary Fast’ Mac EventS\u0026","url":"https://finance.yahoo.com/news/sanofi-ceo-shocks-investors-investment-151500786.html"},{"category":"company","date":1698416280,"headline":"Sanofi (SNY) Beats on Q3 Earnings, to Spin-Off Consumer Unit","id":123461312,"image":"https://media.zenfs.com/en/zacks.com/5d5a6eb884ce28277f39a4369974b5ea","symbol":"SNY","publisher":"Yahoo","summary":"Sanofi (SNY) beats third-quarter estimates for earnings but misses the same for sales. It announces plans to separate its Consumer unit into a new public listed company.","url":"https://finance.yahoo.com/news/sanofi-sny-beats-q3-earnings-141800224.html"},{"category":"company","date":1698415500,"headline":"Pharma Stock Roundup: SNY, MRK, NVS Report Q3 Earnings, FDA Okays PFE, LLY Products","id":123456184,"image":"https://media.zenfs.com/en/zacks.com/f84faa3d65021260b4cd14c75493ef6c","symbol":"SNY","publisher":"Yahoo","summary":"Merck (MRK), Sanofi (SNY) and Novartis (NVS) report third-quarter results. FDA approves Pfizer's (PFE) Penbraya and Eli Lilly's (LLY) Omvoh","url":"https://finance.yahoo.com/news/pharma-stock-roundup-sny-mrk-140500213.html"},{"category":"company","date":1698414812,"headline":"Sanofi CEO says he is opting against 2025 market certainty to create long-term value","id":123461314,"image":"https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png","symbol":"SNY","publisher":"Yahoo","summary":"Sanofi's CEO on Friday said that he was ready to sacrifice market certainty on earnings over the next two years because it means getting the most value out of the French drugmaker over the longer term.  The stock plunged on Friday, wiping 20 billion euros ($21 billion) off its market value, after it abandoned its 2025 profit target under a plan to list its consumer healthcare business and to boost spending on innovative drugs development.  \"We understand there is some short-term disappointment,\" CEO Paul Hudson said in an analyst call after fielding several questions about the higher research and development budget.","url":"https://finance.yahoo.com/news/sanofi-ceo-says-opting-against-135332745.html"},{"category":"company","date":1698410880,"headline":"Sanofi Non-GAAP EPS of €2.55, revenue of €11.96B; reaffirms FY23 outlook","id":123462707,"image":"","symbol":"SNY","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3180872472"},{"category":"company","date":1698410280,"headline":"Amazon, Intel rise; Ford, Chart Industries fall, Friday, 10/27/2023","id":123458414,"image":"","symbol":"SNY","publisher":"Associated Press, The","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=sr5alcsjkv"},{"category":"company","date":1698410220,"headline":"Regeneron (REGN) to Report Q3 Earnings: What's in the Cards?","id":123461315,"image":"https://media.zenfs.com/en/zacks.com/f8e8dd74fec7b16eb85235be391efa80","symbol":"SNY","publisher":"Yahoo","summary":"Investors' focus is likely to be on the performance of lead drug Eylea and the uptake of Eylea HD when Regeneron (REGN) reports its third-quarter 2023 results.","url":"https://finance.yahoo.com/news/regeneron-regn-report-q3-earnings-123700739.html"},{"category":"company","date":1698410040,"headline":"12 Health Care Stocks Moving In Friday's Intraday Session","id":123455826,"image":"","symbol":"SNY","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3181658214"},{"category":"company","date":1698409080,"headline":"Why Barnes Group Shares Are Trading Lower By Around 28%? Here Are Other Stocks Moving In Friday's Mid-Day Session","id":123453727,"image":"","symbol":"SNY","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3181633252"},{"category":"company","date":1698408480,"headline":"LONDON MARKET CLOSE: Poorly-received earnings weigh on European stocks","id":123452638,"image":"","symbol":"SNY","publisher":"Alliance News","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3gnl3asqrr"},{"category":"company","date":1698408000,"headline":"Sanofi shares hit 52-week low amid downwardly revised forecast","id":123462714,"image":"","symbol":"SNY","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3181602971"},{"category":"company","date":1698400440,"headline":"Sanofi (NASDAQ:SNY) Plunges after Announcing Healthcare Spin-Off","id":123462715,"image":"","symbol":"SNY","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3181411124"},{"category":"company","date":1698398100,"headline":"Why Are Stocks Up Today?","id":123455893,"image":"","symbol":"SNY","publisher":"InvestorPlace","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3181352695"},{"category":"company","date":1698397879,"headline":"Moderna: Looking Beyond Covid, The Pipeline Is Promising","id":123450279,"image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1335381149/image_1335381149.jpg?io=getty-c-w1536","symbol":"SNY","publisher":"SeekingAlpha","summary":"Investors should consider accumulating Moderna stock due to its promising pipeline and significant upside potential, despite short-term setbacks. Click here to read my analysis.","url":"https://seekingalpha.com/article/4644369-moderna-beyond-covid-pipeline-promising"},{"category":"company","date":1698397740,"headline":"Sanofi, Dexcom among healthcare movers","id":123451701,"image":"","symbol":"SNY","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3181344755"},{"category":"company","date":1698397283,"headline":"UPDATE 2-French shares lag European peers on Sanofi's dour forecast","id":123461316,"image":"https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png","symbol":"SNY","publisher":"Yahoo","summary":"European shares fell to near seven-month lows on Friday and clocked a second week of losses, with France's blue-chip index leading the way down after Sanofi scrapped its 2025 profit forecast.  The pan-European STOXX 600 closed 0.8% lower, with healthcare the worst performing sector as it fell 2.9% and also hit a seven-month low.  Sanofi sank 18.9% to the bottom of the STOXX 600, wiping nearly $21 billion off the market value of the French drugmaker as it abandoned a target for a 32% operating profit margin for 2025 to focus on \"long-term profitability\".","url":"https://finance.yahoo.com/news/1-french-shares-lag-european-090123216.html"},{"category":"company","date":1698396120,"headline":"Why Is Nikola (NKLA) Stock Up 4% Today?","id":123455894,"image":"","symbol":"SNY","publisher":"InvestorPlace","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3181306726"},{"category":"company","date":1698395160,"headline":"SNY Stock Sinks 15% as Sanofi Plans Consumer Unit Spinoff","id":123455036,"image":"","symbol":"SNY","publisher":"InvestorPlace","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3181285340"},{"category":"company","date":1698395065,"headline":"Sanofi shares fall on lower profit outlook","id":123447838,"image":"https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png","symbol":"SNY","publisher":"Yahoo","summary":"Shares in Sanofi fell 15 per cent on Friday after the French pharmaceutical group announced a lower profit outlook and a spinout of its consumer care unit as it seeks to focus investment in drug research.  Sanofi reaffirmed its earnings per share guidance this year but projected a decline in the low-single digits in 2024 partly due to increased R\u0026D investment.  There would be a “strong rebound” in 2025, Sanofi said.","url":"https://finance.yahoo.com/m/bc17cb85-7bce-31b4-abd5-447162ab0c9d/sanofi-shares-fall-on-lower.html"},{"category":"company","date":1698394080,"headline":"12 Health Care Stocks Moving In Friday's Pre-Market Session","id":123452749,"image":"","symbol":"SNY","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3181263174"},{"category":"company","date":1698393000,"headline":"GLOBAL BROKER RATINGS: BofA cuts Mercedes-Benz to 'neutral'","id":123452350,"image":"","symbol":"SNY","publisher":"Alliance News","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=mopdklwt9b"},{"category":"company","date":1698391800,"headline":"BIVI, VCNX and BHAT among pre-market losers","id":123454378,"image":"","symbol":"SNY","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3181214930"},{"category":"company","date":1698391200,"headline":"Why Intel Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket","id":123453026,"image":"","symbol":"SNY","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3181204208"},{"category":"company","date":1698388020,"headline":"Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday","id":123452756,"image":"","symbol":"SNY","publisher":"InvestorPlace","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3181144167"},{"category":"company","date":1698387480,"headline":"Sanofi Plans to Spin Off Consumer-Healthcare, Pharma Businesses","id":123445575,"image":"","symbol":"SNY","publisher":"Yahoo","summary":"Sanofi plans to spin off its consumer-healthcare and pharmaceutical operations, making it the latest drugmaker to sharpen its focus on prescription medicines by offloading adjacent businesses.","url":"https://finance.yahoo.com/m/be3bec03-165d-3bdd-b229-cb38faefc40e/sanofi-plans-to-spin-off.html"},{"category":"company","date":1698386820,"headline":"Kymera Therapeutics announces first patient dosed in Phase 2 trial of KT-474","id":123455376,"image":"","symbol":"SNY","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3181125304"},{"category":"company","date":1698386420,"headline":"UPDATE 2-French drugmaker Sanofi considers listing consumer unit late next year","id":123445577,"image":"https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png","symbol":"SNY","publisher":"Yahoo","summary":"Sanofi has mapped out a separate listing of its consumer healthcare business from the fourth quarter of next year, the French drugmaker said on Friday, adding it plans to boost drug development spending at its core business.  \"Sanofi is reviewing potential separation scenarios, but believes that the most likely path would be through a capital markets transaction, by creating a listed entity headquartered in France,\" Paris-listed Sanofi said in a statement.  The timing of the potential listing, which Sanofi said would not happen before the fourth quarter of 2024, would be set to maximize value creation for shareholders.","url":"https://finance.yahoo.com/news/1-french-drugmaker-sanofi-considers-060020110.html"},{"category":"company","date":1698386400,"headline":"Sanofi Plans Consumer Spinoff, Sees Profit Hit Next Year -- Earnings Review","id":123490438,"image":"https://mw3.wsj.net/mw5/content/logos/mw_logo_social.png","symbol":"SNY","publisher":"MarketWatch","summary":"By Adria Calatayud Sanofi reported results for the third quarter on Friday. Here is what you need to know: SALES: The French pharmaceutical giant reported...","url":"https://www.marketwatch.com/story/sanofi-plans-consumer-spinoff-sees-profit-hit-next-year-earnings-review-a573104d"},{"category":"company","date":1698385260,"headline":"Sanofi shares skid as French drugmaker outlines higher R\u0026D expenses, taxes","id":123490439,"image":"https://images.mktw.net/im-876683/social","symbol":"SNY","publisher":"MarketWatch","summary":"Shares of French drugmaker Sanofi fell as much as 16% on Friday after hiking its research-and-development expense guidance as well as its expectations for...","url":"https://www.marketwatch.com/story/sanofi-shares-skid-as-french-drugmaker-outlines-higher-r-d-expenses-taxes-1bd21dc1"},{"category":"company","date":1698384960,"headline":"Sanofi reports Q3 Business EPS of EUR 2.55, down 11.5% on reported basis","id":123462728,"image":"","symbol":"SNY","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3181096365"},{"category":"company","date":1698384780,"headline":"Shares of Amazon, Capital One, Intel climb after earnings beats, as NatWest and Sanofi tumble on warnings, and other stocks on the move","id":123483573,"image":"https://images.mktw.net/im-876690/social","symbol":"SNY","publisher":"MarketWatch","summary":"Shares in Amazon, NatWest, Intel, Sanofi, Decker, Ford, DexCom and Enphase were all active in regular trading.","url":"https://www.marketwatch.com/story/shares-of-amazon-intel-climb-after-earnings-beats-as-natwest-and-sanofi-tumble-on-warnings-and-other-stocks-on-the-move-0451fbda"},{"category":"company","date":1698384660,"headline":"Sanofi: Q3 Earnings Snapshot","id":123452642,"image":"","symbol":"SNY","publisher":"Associated Press, The","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=ddj96tp9ul"},{"category":"company","date":1698384660,"headline":"Press Release: Specialty Care growth, strong launch uptake of Beyfortus® and ALTUVIIIO® drive solid Q3 results","id":123445579,"image":"https://media.zenfs.com/en/globenewswire.com/9e521264632e7a9a44e3450108999128","symbol":"SNY","publisher":"Yahoo","summary":"Specialty Care growth, strong launch uptake of Beyfortus® and ALTUVIIIO® drive solid Q3 results Paris, October 27, 2023 Q3 2023 sales growth of 3.2% at CER and business EPS(1) decrease of 2.1% at CER Specialty Care grew 13.5% driven by Dupixent® (€2,847 million, +32.8%) and ALTUVIIIO® more than offsetting the impact of Aubagio® generic competition in the U.S.Stable Vaccines sales (-0.6%) benefited from strong Beyfortus® launch offsetting lower influenza vaccines salesGeneral Medicines core asset","url":"https://finance.yahoo.com/news/press-release-specialty-care-growth-053100774.html"},{"category":"company","date":1698384600,"headline":"Sanofi Will Carve Out Consumer Health Division in Bid to Invest More in Science","id":123445584,"image":"","symbol":"SNY","publisher":"Yahoo","summary":"The stand-alone division will be the latest addition to a growing list of such public companies recently spun out of larger drugmakers.","url":"https://finance.yahoo.com/m/e2daebf8-6369-329c-b258-5df09d601ac7/sanofi-will-carve-out.html"},{"category":"company","date":1698384600,"headline":"Sanofi: considering consumer unit listing from late next year","id":123445582,"image":"https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png","symbol":"SNY","publisher":"Yahoo","summary":"French drugmaker Sanofi said on Friday it was looking into the separate listing of its Consumer Healthcare business from the fourth quarter of next year and that it plans to boost drug development at its core business.  The timing for the spin-off, which Sanofi said won't happen before the the fourth quarter of 2024, will be set to maximize value creation for shareholders, Sanofi said, adding that it would consult with employee representatives on any planned deal.  Sanofi also said it expects 2024 adjusted earning per share to decline by a \"low-single digit\" percentage, citing increased spending on research and development and a higher tax rate, followed by a  strong rebound in 2025.","url":"https://finance.yahoo.com/news/sanofi-considering-consumer-unit-listing-053000367.html"},{"category":"company","date":1698384600,"headline":"Press Release: Sanofi Enters Next Chapter of Play to Win Strategy","id":123445580,"image":"https://media.zenfs.com/en/globenewswire.com/9e521264632e7a9a44e3450108999128","symbol":"SNY","publisher":"Yahoo","summary":"Sanofi Enters Next Chapter of Play to Win Strategy Increases investments in its pipeline to fully realize long-term growth potential, bolstered by successful launches and R\u0026D progress.Launches strategic cost initiatives, with most of the savings to be reallocated to fund innovation and growth drivers.Announces intention to separate the Consumer Healthcare Business at the earliest in Q4 2024 via the creation of a publicly listed entity headquartered in France.Reiterates capital allocation policy","url":"https://finance.yahoo.com/news/press-release-sanofi-enters-next-053000963.html"},{"category":"company","date":1698384360,"headline":"Sanofi executing EUR 2.7B cost savings plan, updates on spinoff plans","id":123462730,"image":"","symbol":"SNY","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3181086931"},{"category":"company","date":1698384300,"headline":"Sanofi says capital allocation policy remains unchanged","id":123462731,"image":"","symbol":"SNY","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3181086140"},{"category":"company","date":1698384240,"headline":"Sanofi reiterates 2023 guidance, provides preliminary 2024 and 2025 outlook","id":123462732,"image":"","symbol":"SNY","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3181085351"},{"category":"company","date":1698384060,"headline":"TOP NEWS: Sanofi shares tumble as consumer business spin-off confirmed","id":123452643,"image":"","symbol":"SNY","publisher":"Alliance News","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3rmi2lz7vq"},{"category":"company","date":1698383160,"headline":"Sanofi stock dips on plans to spin off consumer healthcare unit","id":123462734,"image":"","symbol":"SNY","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3181069939"},{"category":"company","date":1698382560,"headline":"Ford, Sanofi, Enphase Energy And Other Big Stocks Moving Lower In Friday's Pre-Market Session","id":123451794,"image":"","symbol":"SNY","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3181061489"},{"category":"company","date":1698381480,"headline":"Shares of Amazon, Intel climb after earnings beats, as NatWest and Sanofi tumble on warnings, and other stocks on the move","id":123452768,"image":"","symbol":"SNY","publisher":"MarketWatch","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3181046315"},{"category":"company","date":1698379980,"headline":"Sanofi Shares Tumble After Warning of Profit Hit From Investment, Taxes","id":123490440,"image":"https://mw3.wsj.net/mw5/content/logos/mw_logo_social.png","symbol":"SNY","publisher":"MarketWatch","summary":"By Adria Calatayud Shares of Sanofi fell sharply after the company warned it expects business earnings for next year to be hit by its plans to boost...","url":"https://www.marketwatch.com/story/sanofi-shares-tumble-after-warning-of-profit-hit-from-investment-taxes-2580808d"},{"category":"company","date":1698377700,"headline":"Earnings Scheduled For October 27, 2023","id":123451766,"image":"","symbol":"SNY","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3180997936"},{"category":"company","date":1698373440,"headline":"Sanofi Backs Guidance After Earnings, Sales Miss Views","id":123490442,"image":"https://mw3.wsj.net/mw5/content/logos/mw_logo_social.png","symbol":"SNY","publisher":"MarketWatch","summary":"By Adria Calatayud Sanofi confirmed its 2023 guidance after it reported business earnings and sales that came in slightly below consensus forecasts, with...","url":"https://www.marketwatch.com/story/sanofi-backs-guidance-after-earnings-sales-miss-views-f94a5ab1"},{"category":"company","date":1698373440,"headline":"Sanofi 3Q Net Pft EUR2.525B","id":123490441,"image":"https://mw3.wsj.net/mw5/content/logos/mw_logo_social.png","symbol":"SNY","publisher":"MarketWatch","summary":"By Adria Calatayud Sanofi confirmed its 2023 guidance after it reported business earnings and sales that came in slightly below consensus forecasts, with...","url":"https://www.marketwatch.com/story/sanofi-3q-net-pft-eur2-525b-903dd769"},{"category":"company","date":1698372300,"headline":"Sanofi Plans to Split Consumer-Healthcare, Pharma Businesses -- Update","id":123490443,"image":"https://mw3.wsj.net/mw5/content/logos/mw_logo_social.png","symbol":"SNY","publisher":"MarketWatch","summary":"By Adria Calatayud Sanofi plans to split its consumer-healtchare and pharmaceutical operations, making it the latest big drugmaker to sharpen its focus on...","url":"https://www.marketwatch.com/story/sanofi-plans-to-split-consumer-healthcare-pharma-businesses-update-d54891fd"},{"category":"company","date":1698370620,"headline":"Sanofi Plans to Spin off Consumer Healthcare Business","id":123490444,"image":"https://mw3.wsj.net/mw5/content/logos/mw_logo_social.png","symbol":"SNY","publisher":"MarketWatch","summary":"By Adria Calatayud Sanofi said it plans to spin off its consumer-healthcare unit into a publicly listed entity, making it the latest pharmaceutical giant to...","url":"https://www.marketwatch.com/story/sanofi-plans-to-spin-off-consumer-healthcare-business-a20bb5eb"},{"category":"company","date":1698369300,"headline":"US Stocks Waver, Tech Outperforms As September Inflation Data Solidifies Interest Rate Hold; Oil Giants Fall: What's Driving Markets Friday?","id":123456410,"image":"","symbol":"SNY","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3181723399"},{"category":"company","date":1698367080,"headline":"GLOBAL BRIEFING: Amazon shares rise as cloud boosts third quarter","id":123452647,"image":"","symbol":"SNY","publisher":"Alliance News","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=wkb7nldnlc"},{"category":"company","date":1698314100,"headline":"Concurrent use of COVID and flu shots is linked to stroke risk in older adults","id":123425564,"image":"","symbol":"SNY","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3179281772"},{"category":"company","date":1698313440,"headline":"Notable earnings before Friday's open","id":123419043,"image":"","symbol":"SNY","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3179263513"},{"category":"company","date":1698311280,"headline":"Sanofi Sales, Business Profit Expected to Fall -- Earnings Preview","id":123432163,"image":"https://mw3.wsj.net/mw5/content/logos/mw_logo_social.png","symbol":"SNY","publisher":"MarketWatch","summary":"By Adria Calatayud Sanofi is scheduled to report results for the third quarter on Friday. Here is what you need to know: SALES FORECAST: The French...","url":"https://www.marketwatch.com/story/sanofi-sales-business-profit-expected-to-fall-earnings-preview-9a22b788"},{"category":"company","date":1698290400,"headline":"Looking Into Sanofi's Recent Short Interest","id":123431306,"image":"","symbol":"SNY","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3179842239"},{"category":"company","date":1698235320,"headline":"GSK and Other Drugmakers Push Forward With RSV Vaccines Amid Shortages","id":123426438,"image":"https://images.barrons.com/im-39167865/social","symbol":"SNY","publisher":"MarketWatch","summary":"The U.K. drugmaker GSK is seeking to expand regulatory approval for its new respiratory syncytial virus vaccine to include younger adults.","url":"https://www.marketwatch.com/articles/gsk-pfizer-sanofi-stock-rsv-vaccine-32b94864"},{"category":"company","date":1698183840,"headline":"Sanofi Stock Relative Strength Rating Jumps To 84: One To Watch","id":123378923,"image":"","symbol":"SNY","publisher":"Yahoo","summary":"Sanofi stock shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 80 to 84.","url":"https://finance.yahoo.com/m/9566f69e-5e5b-3809-8ed7-edf9c96a67f9/sanofi-stock-relative.html"},{"category":"company","date":1698145500,"headline":"A new RSV shot for infants is in short supply","id":123364032,"image":"","symbol":"SNY","publisher":"Associated Press, The","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=z8n73x4cpg"},{"category":"company","date":1698145320,"headline":"Bristol-Myers was only firm that made real bid for Mirati Therapeutics; BMY offered $140/shr in April 2022","id":123364033,"image":"","symbol":"SNY","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3175372339"},{"category":"company","date":1698144660,"headline":"Bristol-Myers was only firm that made real offer for Mirati Therapeutics","id":123364035,"image":"","symbol":"SNY","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3175355917"},{"category":"company","date":1698144360,"headline":"Bristol-Myers was only firm that made firm offer for Mirati Therapeutics","id":123364037,"image":"","symbol":"SNY","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3175349600"},{"category":"company","date":1698067693,"headline":"Roche Follows Merck, Sanofi Into A Red-Hot Immunology Space With A $7.1 Billion Buyout","id":123338569,"image":"https://media.zenfs.com/en/ibd.com/3d7cc7e4180e71e32482f01db0cdb69e","symbol":"SNY","publisher":"Yahoo","summary":"Roche said Monday it would buy an experimental immunology drug from Roivant and Pfizer for $7.1 billion, and ROIV stock rose.","url":"https://finance.yahoo.com/m/9bb9c3fc-6c79-33bd-b93e-a761560174ff/roche-follows-merck%2C-sanofi.html"},{"category":"company","date":1698046320,"headline":"Dupixent CRL 'unfortunate' for Regeneron, but TD Cowen sees path forward","id":123343983,"image":"","symbol":"SNY","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3173244930"},{"category":"company","date":1698040020,"headline":"US FDA asks Regeneron, Sanofi for more data on Dupixent for urticaria","id":123343985,"image":"","symbol":"SNY","publisher":"Alliance News","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=jbs26b12gj"},{"category":"company","date":1698027420,"headline":"Amazon, Alphabet, Meta, Intel Q3 Earnings This Week: Will Mega-Caps Shatter Forecasts And Revive Market?","id":123336812,"image":"","symbol":"SNY","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3173008326"},{"category":"company","date":1698001200,"headline":"Press Release: Dupixent® (dupilumab) Phase 3 Results show sustained efficacy for up to one year in children 1 to 11 years of age with eosinophilic esophagitis (EoE)","id":123328588,"image":"https://media.zenfs.com/en/globenewswire.com/9e521264632e7a9a44e3450108999128","symbol":"SNY","publisher":"Yahoo","summary":"Dupixent® (dupilumab) Phase 3 Results show sustained efficacy for up to one year in children 1 to 11 years of age with eosinophilic esophagitis (EoE) Late-breaking presentation at ACG 2023 showed histologic and endoscopic improvements were maintained with no new safety signals to week 52 with higher dose Dupixent in these children Data reinforce the role of type 2 inflammation in EoE and the importance of targeting both IL-4 and IL-13 pathwayssBLA for Dupixent to treat children aged 1 to 11 year","url":"https://finance.yahoo.com/news/press-release-dupixent-dupilumab-phase-190000583.html"},{"category":"company","date":1698001140,"headline":"Dupixent® (dupilumab) Phase 3 Results Show Sustained Efficacy for Up to One Year in Children 1 to 11 Years of Age with Eosinophilic Esophagitis (EoE)","id":123328589,"image":"https://media.zenfs.com/en/globenewswire.com/2788fcd6c9b4dcf523fc2cc341eb4142","symbol":"SNY","publisher":"Yahoo","summary":"Late-breaking presentation at ACG 2023 showed histologic and endoscopic improvements were maintained with no new safety signals to week 52 with higher dose Dupixent in these children Data reinforce the role of type 2 inflammation in EoE and the importance of targeting both IL-4 and IL-13 pathways sBLA for Dupixent to treat children aged 1 to 11 years with EoE is under Priority Review in the U.S.; if approved, Dupixent would be the first and only FDA-approved treatment for these children with EoE","url":"https://finance.yahoo.com/news/dupixent-dupilumab-phase-3-results-185900450.html"},{"category":"company","date":1697959140,"headline":"Earnings week ahead: Amazon, Microsoft, Alphabet, Meta, Ford, GM and more","id":123326969,"image":"","symbol":"SNY","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3172308990"},{"category":"company","date":1697947500,"headline":"Regeneron, Sanofi announce results from Phase 3 trial evaluating Dupixent","id":123343988,"image":"","symbol":"SNY","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3172632414"},{"category":"company","date":1697827399,"headline":"UPDATE 1-Sanofi seeing 'unprecedented' demand for RSV therapy","id":123291482,"image":"https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png","symbol":"SNY","publisher":"Yahoo","summary":"French drugmaker Sanofi said on Friday it was seeing an \"unprecedented level\" of demand for its antibody therapy to prevent respiratory syncytial virus (RSV), a leading cause of hospitalizations in infants.  The therapy, branded Beyfortus, was approved in July to prevent RSV in infants and toddlers.  Before the approval of Sanofi's drug, Swedish Orphan Biovitrum's treatment, Synagis, was the only approved preventive therapy in the United States for high-risk infants.","url":"https://finance.yahoo.com/news/1-sanofi-seeing-unprecedented-demand-184319288.html"},{"category":"company","date":1697795760,"headline":"First Week of June 2024 Options Trading For Sanofi (SNY)","id":123291912,"image":"","symbol":"SNY","publisher":"Stock Options Channel","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3169954380"},{"category":"company","date":1697777280,"headline":"FDA rejects Regeneron-Sanofi's Dupixent application for chronic hives, wants more data","id":123317153,"image":"","symbol":"SNY","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3170513075"},{"category":"company","date":1697774640,"headline":"Regeneron, Sanofi update on Dupixent sBLA in Chronic Spontaneous Urticaria","id":123317154,"image":"","symbol":"SNY","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3170449112"}]}